Gyre Therapeutics, Inc. (GYRE) Reports Q2 EPS of $0.01
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St climbs after Fed's Waller says he could support rate hold
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
August 13, 2024 6:00 AM EDTReceived NMPA approval of avatrombopag maleate tablets for the treatment of CLD-associated thrombocytopenia, expanding rare disease product lines
Received IND approval from NMPA to evaluate F230 for the treatment of pulmonary arterial hypertension
U.S. IND submission for F351 in MASH-associated liver fibrosis expected in late 2024 and data readout from Phase 3 trial in CHB-associated liver fibrosis in the PRC expected by early 2025
Cash and cash equivalents totaled $16.1 million as of June 30, 2024
SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (Gyre) (Nasdaq:... More
